Rocket Lab (RKLB) Stock Drops 6% as $3 Billion Dilution Fear Hits Wall Street

TLDR

• Rocket Lab stock dropped 6.34% after announcing a $3 billion at-the-market equity program, triggering dilution fears
• The sell-off was worsened by profit-taking following RKLB’s addition to the Nasdaq-100
• Q1 revenue came in at $200.35 million, up 63.4% year over year, beating the $189.65 million estimate
• Analyst consensus sits at Moderate Buy with an average price target of $102.76; Deutsche Bank raised its target to $120
• BI Asset Management cut its RKLB position by 79.7% in Q1, selling 122,417 shares

Rocket Lab (RKLB) stock fell 6.34% on Tuesday, opening at $95.12, as investors reacted sharply to the company’s announcement of a $3 billion at-the-market equity offering program.

Rocket Lab USA, Inc., RKLB

The move spooked the market. At-the-market programs allow companies to sell new stock gradually, and investors interpreted the announcement as a signal that management is planning to raise fresh cash — which would dilute existing holders.

The stock had been on a strong run. RKLB is up 36.35% year-to-date and recently hit a 12-month high of $151.00, so some of today’s drop reflects traders locking in profits after that rally.

The Nasdaq-100 addition, which was a positive catalyst not long ago, turned into a sell-the-news event. That’s a common pattern — stocks often rally into an index inclusion and pull back once it’s official.

Competition is also a factor. The recent public debut of SpaceX has drawn attention and capital from the broader space sector, pulling some momentum away from Rocket Lab.

Q1 Results Were Solid

Just weeks ago, Rocket Lab posted its strongest quarterly revenue to date. Q1 revenue came in at $200.35 million, a 63.4% jump from the same period last year, comfortably beating the $189.65 million consensus estimate.

EPS came in at -$0.07, in line with expectations and an improvement from the -$0.12 posted in Q1 2025. The company still carries a negative net margin of 26.87% and a negative return on equity of 11.72%.

Analysts expect full-year EPS of -$0.29. Rocket Lab is growing fast but is not yet profitable.

Analyst Targets Remain Elevated

Wall Street hasn’t walked away from the stock. Deutsche Bank raised its price target from $73 to $120 in May, keeping a Buy rating. Roth MKM lifted its target from $90 to $100, also with a Buy. Cantor Fitzgerald reiterated an Overweight rating in late May.

The consensus across 21 analysts sits at Moderate Buy, with an average target of $102.76 — still above where the stock is trading today.

Not everyone is bullish. Wells Fargo initiated coverage with an Equal Weight rating and a $60 target, and BTIG Research holds a Hold rating.

On the institutional side, BI Asset Management slashed its RKLB position by 79.7% in Q1, selling 122,417 shares and cutting its holding to just 31,259 shares worth around $2 million. However, Vanguard Group increased its stake by 13.4% in Q4, adding 5.6 million shares. Overall, 71.78% of the stock is held by institutional investors.

Insider activity is worth noting too. CFO Adam Spice sold 62,744 shares at an average of $142.57 in late May, while insider Frank Klein sold 44,390 shares at the same price. Both sales were made under pre-arranged 10b5-1 plans to cover tax obligations on vesting equity awards.

RKLB currently trades below its 50-day moving average of $106.79 but well above its 200-day average of $84.38.

The post Rocket Lab (RKLB) Stock Drops 6% as $3 Billion Dilution Fear Hits Wall Street appeared first on CoinCentral.